Moomoo AI 已提取核心信息
On February 22, 2024, Bristol-Myers Squibb successfully completed a significant public offering of various notes totaling $11.25 billion. The offering included Floating Rate Notes due 2026 and Fixed Rate Notes with maturity dates ranging from 2026 to 2064, with interest rates between 4.900% and 5.650%. The notes were issued under an Indenture agreement with The Bank of New York Mellon as trustee. Bristol-Myers Squibb intends to allocate a portion of the net proceeds towards funding its proposed acquisitions of Karuna Therapeutics, Inc. and RayzeBio, Inc., as well as related fees and expenses. Remaining proceeds are earmarked for general corporate purposes. The offering is not dependent on the completion of the acquisitions; however, if the acquisition of Karuna does not occur by a specified date, the company will be required to redeem the notes at a price of 101% of their aggregate principal amount plus accrued interest. The notes were sold under an underwriting agreement dated February 14, 2024, with the terms detailed in a Prospectus Supplement filed with the SEC.
On February 22, 2024, Bristol-Myers Squibb successfully completed a significant public offering of various notes totaling $11.25 billion. The offering included Floating Rate Notes due 2026 and Fixed Rate Notes with maturity dates ranging from 2026 to 2064, with interest rates between 4.900% and 5.650%. The notes were issued under an Indenture agreement with The Bank of New York Mellon as trustee. Bristol-Myers Squibb intends to allocate a portion of the net proceeds towards funding its proposed acquisitions of Karuna Therapeutics, Inc. and RayzeBio, Inc., as well as related fees and expenses. Remaining proceeds are earmarked for general corporate purposes. The offering is not dependent on the completion of the acquisitions; however, if the acquisition of Karuna does not occur by a specified date, the company will be required to redeem the notes at a price of 101% of their aggregate principal amount plus accrued interest. The notes were sold under an underwriting agreement dated February 14, 2024, with the terms detailed in a Prospectus Supplement filed with the SEC.
2024年2月22日，百时美施贵宝成功完成了总额为112.5亿美元的各种票据的重大公开募股。此次发行包括2026年到期的浮动利率票据和到期日介于2026年至2064年之间的固定利率票据，利率在4.900％至5.650％之间。这些票据是根据契约协议发行的，纽约梅隆银行是受托人。百时美施贵宝打算将部分净收益用于为其对Karuna Therapeutics, Inc.和RayzeBio, Inc. 的拟议收购以及相关费用和支出提供资金。剩余收益专用于一般公司用途。此次发行不取决于收购的完成；但是，如果未在指定日期之前收购Karuna，则公司将被要求以本金总额的101％加上应计利息的价格赎回票据。这些票据是根据2024年2月14日的承保协议出售的，其条款详见向美国证券交易委员会提交的招股说明书补充文件。
2024年2月22日，百时美施贵宝成功完成了总额为112.5亿美元的各种票据的重大公开募股。此次发行包括2026年到期的浮动利率票据和到期日介于2026年至2064年之间的固定利率票据，利率在4.900％至5.650％之间。这些票据是根据契约协议发行的，纽约梅隆银行是受托人。百时美施贵宝打算将部分净收益用于为其对Karuna Therapeutics, Inc.和RayzeBio, Inc. 的拟议收购以及相关费用和支出提供资金。剩余收益专用于一般公司用途。此次发行不取决于收购的完成；但是，如果未在指定日期之前收购Karuna，则公司将被要求以本金总额的101％加上应计利息的价格赎回票据。这些票据是根据2024年2月14日的承保协议出售的，其条款详见向美国证券交易委员会提交的招股说明书补充文件。
有用
没用